West Virginia Rural Health Transformation grant will support a recovery-to-work initiative in nine counties, connecting individuals with employment opportunities and ongoing recovery support.

Orlando, FL

Ascension Recovery Services (Ascension RS), the leading national behavioral health consulting, development and management company, has been awarded $1.5 million through West Virginia’s Rural Health Transformation Program (RHTP) to help individuals affected by substance use disorder (SUD) return to the workforce and build lasting financial independence.

Announced by West Virginia Governor Patrick Morrisey on October 13, the award is part of the state’s Health to Prosperity initiative, which connects improved health outcomes with workforce participation and economic stability. The funding will support the Ascension RS Return-to-Work program across nine counties: Monongalia, Marion, Logan, McDowell, Mercer, Mingo, Raleigh, Wayne and Wyoming.

Connecting Recovery with Long-Term Employment

For individuals recovering from substance use disorder, completing treatment is one step toward rebuilding their lives. Finding employment, navigating workplace expectations and maintaining recovery can be challenging, particularly in rural communities where services and resources may be limited.

The Ascension RS initiative connects individuals with recovery resources, workforce opportunities and personalized support that continues beyond job placement.

“Recovery is about so much more than achieving sobriety. It’s about helping people rebuild their lives, restore relationships and regain a sense of purpose,” said Doug Leech, founder and chief executive officer, Ascension Recovery Services. “Meaningful employment can be a powerful part of that process. This investment allows us to help more West Virginians move from treatment and recovery into stable employment, while giving them the ongoing support they need to succeed.”

The program will coordinate with employers, healthcare providers, recovery organizations and community partners to help individuals overcome barriers to employment while supporting businesses seeking to build and retain a reliable workforce.

Key components of the initiative include:

• · Recovery and Care Navigation: Connecting participants with appropriate substance use disorder treatment, behavioral health services, peer recovery support and community resources.
• · Workforce Readiness and Job Placement: Helping individuals assess employment readiness, identify suitable opportunities and navigate the hiring process.
• · Employer Partnerships: Working directly with businesses to support recruitment, workplace reintegration and appropriate accommodations for employees in recovery.
• · Ongoing Recovery and Employment Support: Maintaining engagement after job placement to help individuals manage challenges, prevent unnecessary workforce disruption and sustain long-term employment.
• · Measurable Outcomes: Tracking workforce participation, successful job placement and employment retention to evaluate program effectiveness and support future expansion.

Strengthening Rural Communities Through Recovery

The program will emphasize sustained employment, including 180-day job retention, rather than focusing solely on initial placement. This longer-term approach recognizes that recovery and workforce success require continuity, coordination and support.

“West Virginia has made significant investments in addressing substance use disorder, and this initiative represents an important opportunity to build on that progress,” Leech added. “When we connect recovery with employment, we create opportunities for individuals to become more independent, for families to become more stable and for communities to grow stronger.”

The $1.5 million award is part of the nearly $200 million West Virginia received through the federal Rural Health Transformation Program to expand healthcare access, improve health outcomes and strengthen workforce participation.

About Ascension Recovery Services

Ascension Recovery Services (Ascension RS) is a national leader in behavioral health program development and management, partnering investors, hospitals, health systems, government entities, non-profit treatment organizations and tribal lands to accelerate the creation and operation of high-impact substance use disorder (SUD) and mental health treatment programs. As the nation’s first Substance Use Disorder Management Services Organization (SUD-MSO), ARS integrates capital planning, facility design, licensure and accreditation, staffing, payer contracting, marketing, and long-term management into a single, scalable model. With more than a decade of experience and projects spanning 80 organizations across 35 states, Ascension RS supports every level of care—including Residential Treatment Centers, Intensive Outpatient Programs, Partial Hospitalization Programs, Sober Living Homes, and hospital-based treatment lines—delivering measurable clinical and financial results for its partners. Headquartered in Orlando, Florida Ascension RS combines financial expertise, clinical excellence, and compassionate leadership to expand access to sustainable recovery nationwide. For more information, visit www.ascensionrs.com.

Media Contact Details
Amanda Cecconi
Email: Send Email
Phone: 615.473.7536

Pasco Argentinian food company is acquired by DHS, this Friday for $375 million, marking the company's fourth major acquisition

WASHINGTON, DC, Tuesday, October 20th, 2026

DHS Ventures & Holdings agreed to buy a controlling stake in Pasco, an Argentinian food company, on Tuesday for $375 million, marking the company’s fourth major acquisition in emerging markets in the past two years.

With the deal, DHS Ventures & Holdings, the Washington, DC-based private equity firm will acquire Zanca Investimentos, the controlling shareholder of Latin American pasta, biscuit, and powdered-beverage maker Pasco. The deal is expected to be finalized later this year, the company said in a news release.

“With its outstanding portfolio of popular consumer brands, Pasco is an excellent strategic fit for DHS Ventures & Holdings and our business in Latin America,” DHS Ventures Vice Chairman, Fernando Aguirre was quoted as saying Thursday. “Argentina is one of the largest economies in Latin America and this acquisition will allow us to accelerate our growth and improve our margins in the region. “This means more growth for the core Pasco business and our well-loved DHS Ventures initiatives.”

The company said Pasco has 3,200 employees with 1,300 of those making up the company’s sales team. Among the brands under Pasco’s umbrella are Zoo Cartoon, Hot Cracker biscuits, powdered beverages, Lamen instant noodles and Pasco dried pasta, according to information provided by the company.

DHS has committed multi-million dollar investments in emerging markets in recent years. Last year, the company announced a $450 million investment into Marzipan, a sales and distribution company based in West Peru; a separate $50 million acquisition of Egypt’s top cereal company, Hoshea Distribution; and it won a months-long bidding war for an 86 percent stake in Egyptian company Bisco.

ABOUT DHS Ventures & Holdings

DHS Ventures & Holdings is a high-stakes investment, private equity, and venture capital firm. Our strategic insights and innovative programming build and sustain strong corporate and brand reputations. We provide our clients with counsel and program development across the spectrum of public relations, public affairs, reputation and crisis management, digital strategy, advertising and other communications services. Our clients are companies, industry associations, nonprofit organizations, professional services firms, and other large organizations.

Media Contact Information

Kali Harrisburg, Vice President of Communications

DHS Ventures & Holdings

1500 K Street, NW

Washington, DC 10005

[email protected]

202-719-0398

As online interest in BPC-157 continues to climb, California Trim Clinic is addressing the surge in patient questions surrounding the peptide’s potential role in recovery, repair, and longevity conversations. Nicknamed “Wolverine in a vial” in some online spaces for its combination with the TB-500 peptide, BPC-157 has become the subject of growing curiosity, especially among patients seeking structured, physician-guided insight instead of hype. This release explores why the peptide is drawing so much attention, what patients are actually asking, and how California Trim Clinic approaches these conversations through a safety-first lens, often beginning with a confidential discovery call designed to evaluate whether peptide therapy is appropriate for the individual.

Westlake Village, CA

What Are BPC-157 and TB-500 and Why Are Patients Calling It “Wolverine in a Vial”?

BPC-157 and TB-500 are peptides that have attracted growing attention in patient conversations around repair, recovery, and performance support. While interest has expanded quickly, so has the amount of confusion surrounding what it is, what it does, and how it is being discussed online.

In some corners of the internet, BPC-157 and TB-500 have picked up the nickname “Wolverine in a vial” because of the way people talk about it in connection with recovery and repair. That phrase has helped fuel curiosity, but it has also created a wave of questions from patients trying to separate viral language from real clinical context.

California Trim Clinic is seeing that curiosity play out in search behavior, patient questions, and broader peptide-related conversations, particularly among patients now moving away from guesswork and into physician-prescribed compounded peptide therapy programs designed for structured, medically supervised outcomes.

“Wolverine in a Vial”? Why This Peptide Is Suddenly Everywhere

BPC-157 and TB-500 are no longer a niche term reserved for peptide forums and biohacking circles. It is now showing up in broader consumer search patterns, patient questions, and online health discussions at a much faster pace.

That shift is being driven by a mix of curiosity, anecdotal buzz, and growing interest in repair-based approaches to wellness. People are not just asking what BPC-157 and TB-500 are. They are asking how long it lasts, how quickly it works, whether it is safe, and whether it belongs in conversations around longevity.

California Trim Clinic views this moment as a signal that patients are moving from passive curiosity into active decision-making, often beginning by exploring how compounded peptide therapy fits into a structured, physician-guided care model built for safety, consistency, and long-term outcomes.

Understanding BPC-157 and Its Role in Recovery and Repair

BPC-157 is commonly discussed in connection with repair-focused wellness conversations, particularly where patients are interested in recovery support rather than symptom-only strategies. That interest has made it stand out in a peptide landscape that is becoming more visible to mainstream audiences.

For many patients, the appeal is not just about one narrow use case. It is about the broader idea of supporting the body in a more restorative way, especially when conventional options have felt limited, incomplete, or overly focused on temporary management.

Patients moving beyond surface-level interest are increasingly evaluating how BPC-157 fits within regulated compounded peptide protocols that prioritize proper sourcing, dosing accuracy, and clinical oversight, rather than relying on inconsistent or unverified alternatives.

Why Patients Are Flooding Search Results About BPC-157

The search behavior around BPC-157 tells a very clear story. Patients are not casually browsing. They are looking for answers to highly specific questions that point to urgency, uncertainty, and strong personal interest.

Many of those searches focus on speed and timing. People want to know how long BPC-157 lasts, how long it stays in the body, how quickly they may notice anything, and how long they are supposed to use it.

Another major cluster centers around safety and usage, which is why more patients are shifting toward structured evaluation through a guided consultation that clarifies expectations, safety considerations, and appropriate next steps instead of relying on fragmented online information.

From Injury Recovery to Skin Repair: Why BPC-157 Is Entering the Longevity Conversation

BPC-157 is increasingly being discussed as part of a broader longevity and repair conversation. That does not mean it belongs in every wellness plan, but it does explain why interest is expanding beyond narrow niche communities.

Patients are now exploring peptides through a larger framework that includes recovery, resilience, performance, and support for how they feel over time. In that environment, BPC-157 is attracting attention because it appears to sit at the intersection of repair-based curiosity and future-focused wellness thinking.

California Trim Clinic has explored this shift further in its in-depth analysis of BPC-157 for eczema and rosacea and why patients are moving toward repair-based treatment models.

From Symptom Management to Repair: A Growing Shift in Patient Interest

One of the most interesting changes in patient behavior is the growing preference for repair-based language. Instead of asking only how to suppress an issue, patients are increasingly asking whether there are therapies that may better support recovery-oriented strategies.

That shift is especially visible in skin-related conversations. Patients who feel frustrated by cycles of temporary management often begin looking for deeper approaches that align more closely with repair, barrier support, and longer-term wellness goals.

This is where structured care becomes critical, particularly within physician-guided programs designed to move patients beyond repetitive symptom cycles into more stable outcomes.

A Physician-Guided Approach to BPC-157 and Peptide Protocols

As patient curiosity grows, the difference between hype and structure becomes even more important. California Trim Clinic approaches peptide discussions through physician-guided evaluation, not one-size-fits-all assumptions.

That means starting with patient context, health history, and goals. It also means making sure people understand that just because something is trending online does not mean it should be approached casually.

Patients ready to move from information into action typically begin through a structured consultation process that evaluates whether BPC-157 or any peptide protocol is appropriate before moving forward.

BPC-157 Is Gaining Attention, But Context Matters

There is no question that BPC-157 has entered a new level of visibility. The phrase “Wolverine in a vial” may be catchy, but the real story is bigger than a nickname.

The real story is that patients are actively searching for answers about recovery, timing, safety, and whether this peptide deserves the level of attention it is receiving. That makes context more valuable, not less.

California Trim Clinic positions that context within a physician-guided care model designed to help patients navigate compounded peptide therapy with clarity, safety, and structure.

Learn More About Physician-Guided Peptide Therapy

Patients interested in learning more about structured peptide conversations are increasingly moving toward medically guided frameworks instead of navigating fragmented online information.

For many, the next step is not jumping into hype, but understanding how peptide therapy is evaluated, prescribed, and monitored within a real clinical setting.

That process typically begins with a no-obligation discovery call designed to answer questions, evaluate goals, and determine whether compounded peptide therapy is appropriate, or send us a message via our contact form. This is, followed by deeper exploration through regulated compounded peptide therapy programs built around safety, consistency, and long-term outcomes.

Medical Disclaimer

CLINICIAN-SUPERVISED MEDICAL WEIGHT LOSS

MEDICATION SOURCED FROM FDA-REGULATED U.S. COMPOUNDING PHARMACIES

This content is for educational purposes only and does not constitute medical advice. All medications and compounded peptide therapies must be prescribed and monitored by a licensed healthcare provider following appropriate evaluation.

About California Trim Clinic

California Trim Clinic provides physician-guided metabolic health and weight management programs through secure telehealth consultations available nationwide. Treatments are prescribed by licensed providers and sourced through FDA-regulated U.S. compounding pharmacies, ensuring structured, individualized care.

For more information or to begin a consultation, book a Discovery Call with our Care Team.

Media Contact Details
California Trim Clinic
Phone: 8058928077
Website: californiatrimclinic.com